BioInvent International AB (publ) (BINV.ST)
Develops antibody drugs designed to boost the immune system's ability to fight cancer.
23.45+0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-38.3%
The outlook
BINV.ST trades near the lower quarter of its 52-week range and below both its 50- and 200-day moving averages, reflecting weak near-term momentum. Analyst coverage shows a notably bullish average price target roughly 305% above the current price, though the overall sentiment leans bearish. The stock sits at a significant gap between current weakness and analysts' long-term expectations.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range20% of the way from its 52-week low to high
Price targetAvg target +305% vs current price
Analyst price target
~12-month · 3 analysts95.00average target+305.1% vs now
Now 23.45
Low 85.00High 110.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.54B
52-wk high
40.50
52-wk low
19.22
50-day avg
25.37
200-day avg
26.28
Trailing P/E
—